

1 **Progressive worsening of the respiratory and gut microbiome in children during**
2 **the first two months of COVID-19**

3 Running title: **COVID-19 disturbs children's microbiome**

4

5 Rong Xu^{1,4,#}, Pengcheng Liu^{2,#}, Tao Zhang^{3,#}, Qunfu Wu^{3,#}, Mei Zeng², Yingying Ma¹, Xia Jin¹,
6 Jin Xu^{2*}, Zhigang Zhang^{3*}, Chiyu Zhang^{1,4*}

7

- 8 1. Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China
9 2. Children's Hospital of Fudan University, Shanghai 201102, China
10 3. State Key Laboratory for Conservation and Utilization of Bio-Resources in Yunnan, School of
11 Life Sciences, Yunnan University, Kunming, Yunnan 650091, China
12 4. Pathogen Discovery and Evolution Unit, Institut Pasteur of Shanghai, Chinese Academy of
13 Sciences, Shanghai 200031, China.

14 # These authors contributed equally to this work.

15

16 * Correspondence: Chiyu Zhang, Shanghai Public Health Clinical Center, Fudan University,
17 Shanghai 201508, China. Email zhangcy1999@hotmail.com

18 Or Zhigang Zhang, State Key Laboratory for Conservation and Utilization of Bio-Resources in
19 Yunnan, School of Life Sciences, Yunnan University, No. 2 North Cuihu Road, Kunming, Yunnan
20 650091, China. Email: zhangzhigang@ynu.edu.cn.

21 Or Jin Xu, Department of Clinical Laboratory, Children's Hospital of Fudan University, Shanghai
22 201102, China. Email: janexu@fudan.edu.cn

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

23 **Abstract**

24 Children are less susceptible to COVID-19 and manifests lower morbidity and mortality after
25 infection, for which a multitude of mechanisms may be proposed. Whether the normal development
26 of gut-airway microbiome is affected by COVID-19 has not been evaluated. We demonstrate that
27 COVID-19 alters the respiratory and gut microbiome of children. Alteration of the microbiome was
28 divergent between the respiratory tract and gut, albeit the dysbiosis was dominated by genus
29 *Pseudomonas* and sustained for up to 25-58 days in different individuals. The respiratory microbiome
30 distortion persisted in 7/8 children for at least 19-24 days after discharge from the hospital. The gut
31 microbiota showed early dysbiosis towards later restoration in some children, but not others.
32 Disturbed development of both gut and respiratory microbiomes, and prolonged respiratory dysbiosis
33 in children imply possible long-term complications after clinical recovery from COVID-19, such as
34 predisposition to an increased health risk in the post-COVID-19 era.

35

36 **Key words:** SARS-CoV-2/COVID-19; respiratory microbiota; gut microbiota, dysbiosis; children.

37 **Introduction**

38 COVID-19 caused by SARS-CoV-2 has impacted millions of peoples in more than 200 countries
39 around the world^{1,2}. Compared with adults, children appear to be less susceptible to COVID-19 with
40 extremely low morbidity and mortality³⁻⁵; and children with COVID-19 often have mild symptoms
41 with a faster recovery, and better prognosis. The reasons for these are not entirely clear. Early-life
42 development and maturation of human microbiomes shape health status in later life⁶⁻⁹, and delayed
43 development or dysbiosis of the microbiomes during childhood has been linked to predisposition to
44 various diseases in adulthood⁷⁻¹². The effect of COVID-19 on the gut microbiome had just began to
45 be evaluated in adults^{13,14}, but never in children. We recently evaluated the longitudinal effects of
46 COVID-19 on both the respiratory and gut microbiome in adults, and revealed that the respiratory
47 and gut microbiome presented a contemporaneous change from early dysbiosis towards late
48 incomplete restoration during the course of disease (Xu et al., unpublished observation). How
49 COVID-19 impacts on the respiratory and gut microbiomes of children is not known. Here, we report
50 temporal dynamics of respiratory and gut microbiome in children with COVID-19.

51 **Results**

52 **Study cohort**

53 Nine COVID-19 children between 7-139 months old were enrolled in this study together with
54 14 age-matched healthy control children. A total of 103 specimens including 27 sets of paired
55 specimens (at least two of throat swab, nasal swab and feces) were collected from children with
56 COVID-19 ([Supplementary Fig. 1](#)). The children were being followed between 25-58 days after
57 symptom onset. All samples were subjected to high-throughput sequencing of the V4-region of
58 bacterial 16S rRNA gene ([Methods](#)).

59

60 **Respiratory and gut microbiome dynamics in COVID-19**

61 We analyzed the 16S-rRNA gene sequences of all specimens from three body sites, and obtained
62 2,187 sub-OTUs (sOTUs) that represent 15 known phyla including 200 known genera
63 ([Supplementary Table 1](#)). Using the DMM method ([Supplementary method](#)), we identified 8
64 community types ([Fig.1a](#)). The specimens from healthy children clustered into two community types,
65 one bears the signature of stool samples (H-GUT), and another represents the collection of all three
66 kinds of samples (throat swab, nasal swab and feces) (H-MIX). H-GUT is significantly separated
67 from H-MIX ([Fig. 1b](#)), with significantly lower richness and evenness ([Fig.1c](#)). H-GUT was featured
68 by *Moraxella*, a commensal in nasal passages of infants, implying that it might not represent a normal
69 gut microbiome status. Because the development of infant microbiome is influenced by maternal
70 materials from multiple sites (stool, vaginal, oral and skin) among which bacteria from maternal gut
71 being the most important contributor¹⁵, infants and children may share the same or very similar
72 microbial community structures of the nasal cavity, throat and gut^{16,17}. Therefore, H-MIX represents

73 the gut and respiratory tract microbiomes of healthy children. In fact, the nasal cavity, throat and gut
74 still maintain similar microbial structures in adulthood.

75 Bacteria from stool specimens of COVID-19 children fell into three distinct community types
76 (COVID-GUT I-III), and those from nasal and throat swabs formed another three distinct types
77 (COVID-TN I-III) (Fig. 1a). All COVID-19-related types are significantly separated from the type
78 H-MIX except COVID-TN-I that overlaps with H-MIX (Fig. 1b). In particular, three respiratory tract-
79 related types and three GUT-related types of COVID-19 children are also significantly separated from
80 each other, and distinctly different from healthy children. These results indicated that SARS-CoV-2
81 infection significantly changed the gut and respiratory tract microbiota of children, and the separation
82 of bacterial community structures between the gut and respiratory tracts suggested that the normal
83 development of the microbiota may be impaired.

84 All COVID-19-related types showed lower richness and evenness than H-MIX, except for
85 COVID-GUT-I that has the most similarity to H-MIX and relatively normal microbiome structure.
86 There was a gradual decrease from community type I to III for both gut and respiratory tract (Fig. 1c),
87 indicating a progressive deterioration (dysbiosis) of the microbiome. Overall, the dysbiosis appeared
88 to be more severe in the respiratory tract than in the gut.

89

90 **Indicator genera of eight DMM clusters**

91 To characterize eight microbial community types, we identified 35 indicator genera (Fig. 2a).
92 The H-MIX type was characterized by 11 genera, and the predominant commensal bacteria contained
93 *Prevotella*, *Streptococcus*, unclassified *Pasteurellaceae*, and *Actinomyces* (Fig. 2b). Some of the
94 indicator bacteria in H-MIX were shared by the community types COVID-GUT-I (e.g. *Prevotella*,

95 *Porphyromonas*, *Fingoldia*, *Anaerococcus*, etc.) and COVID-TN-I (e.g. *Prevotella*, *Neisseria*,
96 *Fusobacterium*, unclassified *Pasteurellaceae*, *Leptotrichia* etc.). As a dysbiosis status, community
97 type COVID-GUT-III was dominated by *Bacteroides*, as well as *Parasutterella* that is associated with
98 irritable bowel syndrome and other intestinal chronic inflammation¹⁸. Community type COVID-TN-
99 III was dominated by highly abundant *Pseudomonas* and *Herbaspirillum*, and it had higher levels of
100 genera of *Corynebacterium*, *Comamonadaceae*, *Burkholderia*, *Achromobacter*, *Brevundimonas*,
101 *Ralstonia*, *Phyllobacterium*, and *Burkholderiales* than other community types (Fig. 2b). Genus
102 *Pseudomonas* is a notorious human pathogen associated with various diseases (e.g. pneumonia), and
103 the samples were overwhelmed by the dominant species *Pseudomonas veronii* (100% sequence
104 identity)¹⁹. Apart from COVID-TN-III, genus *Pseudomonas* also dominated community type
105 COVID-TN-II with *Streptococcus*, and COVID-GUT-II with *Bacteroides*. Furthermore,
106 *Achromobacter* and *Burkholderia* are associated with cystic fibrosis^{20,21}, and most other genera are
107 environmental bacteria. The predominance of *Pseudomonas* together with the colonization of various
108 environmental bacteria in type COVID-TN-III imply an extreme dysbiosis in upper respiratory tract.

109

110 **The dynamic change of children during COVID-19**

111 Recently, we observed synchronous restoration of the microbiomes of both respiratory tract and
112 the gut towards normal structure in COVID-19 adults within a short time (6-17 days) after symptom
113 onset (Xu et al., unpublished observation). Distinct from adults, the microbiome community
114 compositions were extremely dynamic in children during COVID-19, and the changes of the
115 community types in the respiratory tract and gut were divergent (Fig. 3a). The respiratory (especially
116 nasopharyngeal) microbiome of 7/8 children (except CV05) appeared to evolve from early healthy

117 (H-MIX) or high-diversity community structures (COVID-TN-I) to late low-diversity dysbiosis
118 structure (COVID-TN-III), indicating a steady deterioration in composition and function of the
119 respiratory microbiome despite a fast clinical recovery (Fig. 3a). Surprisingly, the respiratory
120 dysbiosis was sustained at least 19-24 days after discharge (i.e., 42-58 days after symptom onset) in
121 three children (CV01, CV02 and CV09).

122 In contrast, the gut microbiome alternation varied greatly among these COVID-19 children.
123 Improvement or restoration was observed in three children (CV01, CV02 and CV05), but a worsening
124 trend of unstable bacterial genera occurred in another three children (CV03, CV04 and CV09) (Fig.
125 3a). For example, the community type of CV09 improved from COVID-GUT-II to COVID-GUT-I
126 on day 7 after symptom onset, but deteriorated to COVID-GUT-III on day 37. For CV03, whose
127 microbiome got worse from a gut community type COVID-GUT-II on day 19 to a respiratory
128 community type COVID-TN-III on day 27, and returned to COVID-GUT-II on day 43. The shift from
129 a slightly dysbiosis gut community type to a severely dysbiosis respiratory community type implies
130 microbial translocations from respiratory tract to gut. The restoration or worsening of the gut
131 microbiome showed no association with clinical recovery (discharge from the hospital) or the
132 presence or absence of SARS-CoV-2 RNA in the gut (Fig.3a).

133 Our data clearly demonstrate a progressively worsening of microbiome in both the respiratory
134 tract and gut of children during the course of COVID-19. The worsening was predominantly driven
135 by *Pseudomonas* species *P.veronii* (Fig. 3b and Supplementary Fig. 2), which was the most prevalent
136 *Pseudomonas* species identified, and had a relative abundance of over 20% in most COVID-19
137 children. Genus *Streptococcus* (mainly *S.mitis*) also contributed to the worsening of the microbiome²².
138 On the other hand, the presence of probiotic *Bifidobacterium* and the most important butyrate-

139 producing bacteria *Faecalibacterium* were inversely correlated with the existence of *Pseudomonas*
140 (Fig. 3b and Supplementary Fig. 2), despite these beneficial bacteria presented at a very low relative
141 abundance and often decreased in late disease stage.

142

143 **Bacteria–bacteria co-occurrence networks**

144 The co-occurrence network analysis revealed significant microbial cross-talk among different
145 body sites of children with COVID-19 (Fig. 4). There were three main co-occurrence networks
146 identified. Positive co-occurrence relationships were observed within and between bacteria from the
147 respiratory tract and the gut (FDR-adjusted $P < 0.001$, Pearson correlation $r > 0.4$), indicating the
148 presence of frequent bacterial cross-talk between different body sites. Similar to our observation in
149 adults, the co-occurrence networks were relatively separated by different diversity-levels of
150 community types, but not by body sites. For example, bacteria from the community type COVID-
151 TN-III are closely associated with those from COVID-TN-II and COVID-GUT-II (Fig. 4). In this
152 network, *Pseudomonas* was positively correlated with some environmental bacteria. In another two
153 networks, probiotic (e.g. *Bifidobacterium* and *Faecalibacterium*) were mainly correlated with
154 commensals and community types H-MIX, COVID-GUT-I, COVID-TN-I and COVID-TN-II (Fig.
155 4). Therefore, the community types are more representative of microbiome status.

156 Discussion

157 SARS-CoV-2 infection causes damage to multiple organs either through direct infection, or
158 indirectly disrupt host homeostasis, including perturbation of gut and respiratory microbiota in adults.
159 Here, we report the first longitudinal investigation of microbiome with sampling from multiple
160 anatomical sites of children with COVID-19, and present evidence that children have distinct
161 differences compared to adults (Xu, unpublished observations), with respect to the dynamic changes
162 of microbiota during the course of disease. The study of children is a significant feature because early-
163 life microbiome plays important roles in the development of host immunity, metabolism, and neural
164 systems, affecting profoundly health status in later life⁷. The microbiome attains a relatively stable
165 adult-like structure at the age 3 after a highly dynamic initial developmental (months 3-14) phase, a
166 transitional (months 15-30) phase, and finally a stable phase (months 31-46)¹⁶. The development of
167 infants' microbiomes is more easily influenced by various internal (genetic) and external factors (e.g.
168 birth mode, feeding type, siblings, antibiotics, and infection)^{7,9}, and maternal gut strains provide the
169 largest contribution to the microbiome composition¹⁵. Early-life microbiome disruption caused by
170 antibiotics and malnutrition is associated with increased risk of health problems later in childhood
171 and even adulthood, such as developmental retardation, allergic diseases, obesity, diabetes and
172 immune dysfunction^{3-5,23,24}.

173 SARS-CoV-2 infection impaired the respiratory and gut microbiota in both adults and children,
174 but the respiratory and gut microbiome of children and adults faced diverging fates ([Supplementary](#)
175 [Fig. 3](#)). In some mild adult cases, the respiratory and gut microbiomes showed a synchronous
176 restoration from early dysbiosis towards later near-normal structure within a short period (6-17 days),
177 substantially earlier than their clinical recovery (Xu et al. unpublished observation). In children,

178 however, the dynamic changes of the microbiome were divergent between respiratory tract and gut,
179 and the microbiome appeared to be progressively worsening, especially in the respiratory tract for a
180 long period (25-52 days), substantially later than their clinical recovery (12-37 days) ([Supplementary](#)
181 [Fig. 3](#)). In this cohort, six children were older than 3 years of age, and should have relatively stable
182 adult-like microbiome. The dynamic characteristics of the microbiome during COVID-19 implied
183 that children's microbiome is still particularly vulnerable and less resilient than that of the adults even
184 after attaining a stable phase^{7,9,16}. Importantly, the persistent worsening of the microbiomes caused
185 by COVID-19 might impart potential short-term and long-term health problems during childhood and
186 adulthood.

187 We and other have reported that altered respiratory microbiome with reduced bacterial diversity
188 increased the susceptibility of children to acute respiratory tract infections (ARTIs)^{6,8,25-27}. The
189 impaired microbiome in children with COVID-19 is characterized by *Pseudomonas*-dominated
190 community types that favor the colonization and growth of pathogenic and environmental bacteria,
191 and a reduction of some beneficial commensals ([Fig. 4](#)). Probiotic (e.g. *Bifidobacterium*) and
192 butyrate-producing bacteria (e.g. *Faecalibacterium*) that have anti-inflammatory ability were
193 extensively depleted from the gut and respiratory microbiomes of the children especially at late stage
194 of COVID-19 ([Fig. 3b](#))^{28,29}. Low abundance or lack of butyrate-producing bacteria might tolerate
195 low-level inflammation induced by SARS-CoV-2, rendering children more vulnerable to ARTIs and
196 diarrheal diseases^{8,9,30}. In particular, the enrichment of genera *Moraxella* and *Streptococcus* in these
197 COVID-19 children might predispose them to an increased risk of recurrent ARTIs⁶.

198 To the best of our knowledge, this is the first report on the complex dynamics of the gut and
199 respiratory microbiota in children with COVID-19. Disturbed development of both gut and

200 respiratory microbiomes, and prolonged respiratory dysbiosis caused by SARS-CoV-2 infection
201 imply possible short-term and long-term complications after they have recovered from COVID-19,
202 and predispose afflicted children to an increased health risk in later life. Although the long-term
203 outcomes of COVID-19 on children need to be further studied with more extended follow-up and
204 larger cohort, our data suggest that early implementation of various intervention strategies to
205 modulate the microbiome development may provide clinical benefit to children in the post COVID-
206 19 era.

207

208 **Online content**

209 Any methods, additional references, source data, extended data, supplementary information,
210 acknowledgements, details of author contributions and competing interests, and statements of data
211 and number availability are available.

212

- 213 1 Zhu, N. *et al.* A Novel Coronavirus from Patients with Pneumonia in China, 2019. *New Engl J Med* **382**,
214 727-733 (2020).
- 215 2 Zhou, P. *et al.* A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature*
216 **579**, 270-273 (2020).
- 217 3 Guan, W. *et al.* Clinical Characteristics of Coronavirus Disease 2019 in China. *New Engl J Med* **382**, 1708-
218 1720 (2020).
- 219 4 Wu, Z. Y. & McGoogan, J. M. Characteristics of and Important Lessons From the Coronavirus Disease 2019
220 (COVID-19) Outbreak in China Summary of a Report of 72 314 Cases From the Chinese Center for Disease
221 Control and Prevention. *Jama-J Am Med Assoc* **323**, 1239-1242 (2020).
- 222 5 Onder, G., Rezza, G. & Brusaferro, S. Case-Fatality Rate and Characteristics of Patients Dying in Relation
223 to COVID-19 in Italy. *Jama-J Am Med Assoc* **323**, 1775-1776 (2020).
- 224 6 Teo, S. M. *et al.* The Infant Nasopharyngeal Microbiome Impacts Severity of Lower Respiratory Infection
225 and Risk of Asthma Development. *Cell Host Microbe* **17**, 704-715 (2015).
- 226 7 Derrien, M., Alvarez, A. S. & de Vos, W. M. The Gut Microbiota in the First Decade of Life. *Trends Microbiol*
227 **27**, 997-1010 (2019).
- 228 8 Dubourg, G., Edouard, S. & Raoult, D. Relationship between nasopharyngeal microbiota and patient's
229 susceptibility to viral infection. *Expert Rev Anti-Infe* **17**, 437-447 (2019).
- 230 9 Man, W. H., Piters, W. A. A. D. & Bogaert, D. The microbiota of the respiratory tract: gatekeeper to
231 respiratory health. *Nat Rev Microbiol* **15**, 259-270 (2017).

- 232 10 Blanton, L. V. *et al.* Gut bacteria that prevent growth impairments transmitted by microbiota from
233 malnourished children. *Science* **351**, 10.1126/science.aad3311 aad3311 (2016).
- 234 11 Gehrig, J. L. *et al.* Effects of microbiota-directed foods in gnotobiotic animals and undernourished children.
235 *Science* **365**, eaau4732 (2019).
- 236 12 Cox, L. M. *et al.* Altering the Intestinal Microbiota during a Critical Developmental Window Has Lasting
237 Metabolic Consequences. *Cell* **158**, 705-721 (2014).
- 238 13 Gu, S. *et al.* Alterations of the Gut Microbiota in Patients with COVID-19 or H1N1 Influenza. *Clin Infect*
239 *Dis*, ciaa709 (2020).
- 240 14 Zuo, T. *et al.* Alterations in Gut Microbiota of Patients With COVID-19 During Time of Hospitalization.
241 *Gastroenterology*, ciaa709 (2020).
- 242 15 Ferretti, P. *et al.* Mother-to-Infant Microbial Transmission from Different Body Sites Shapes the
243 Developing Infant Gut Microbiome. *Cell Host Microbe* **24**, 133-145.e135 (2018).
- 244 16 Stewart, C. J. *et al.* Temporal development of the gut microbiome in early childhood from the TEDDY
245 study. *Nature* **562**, 583-588 (2018).
- 246 17 Ding, T. & Schloss, P. D. Dynamics and associations of microbial community types across the human body.
247 *Nature* **509**, 357-360 (2014).
- 248 18 Chen, Y. J. *et al.* Parasutterella, in association with irritable bowel syndrome and intestinal chronic
249 inflammation. *J Gastroen Hepatol* **33**, 1844-1852 (2018).
- 250 19 Cheuk, W., Woo, P. C. Y., Yuen, K. Y., Yu, P. H. & Chan, J. K. C. Intestinal inflammatory pseudotumour with
251 regional lymph node involvement: identification of a new bacterium as the aetiological agent. *J Pathol*
252 **192**, 289-292 (2000).
- 253 20 Spilker, T., Vandamme, P. & LiPuma, J. J. Identification and distribution of Achromobacter species in cystic
254 fibrosis. *J Cyst Fibros* **12**, 298-301 (2013).
- 255 21 Jones, A. M. *et al.* Burkholderia cenocepacia and Burkholderia multivorans: influence on survival in cystic
256 fibrosis. *Thorax* **59**, 948-951 (2004).
- 257 22 Mitchell, J. Streptococcus mitis: walking the line between commensalism and pathogenesis. *Mol Oral*
258 *Microbiol* **26**, 89-98 (2011).
- 259 23 Livanos, A. E. *et al.* Antibiotic-mediated gut microbiome perturbation accelerates development of type 1
260 diabetes in mice. *Nat Microbiol* **1**, 16140 (2016).
- 261 24 Grier, A. *et al.* Neonatal gut and respiratory microbiota: coordinated development through time and space.
262 *Microbiome* **6**, 193 (2018).
- 263 25 Man, W. H. *et al.* Bacterial and viral respiratory tract microbiota and host characteristics in children with
264 lower respiratory tract infections: a matched case-control study. *Lancet Resp Med* **7**, 417-426 (2019).
- 265 26 Langevin, S. *et al.* Early nasopharyngeal microbial signature associated with severe influenza in children:
266 a retrospective pilot study. *J. Gen. Virol.* **98**, 2425-2437 (2017).
- 267 27 Piters, W. A. A. D. *et al.* Nasopharyngeal Microbiota, Host Transcriptome, and Disease Severity in Children
268 with Respiratory Syncytial Virus Infection. *Am J Resp Crit Care* **194**, 1104-1115 (2016).
- 269 28 Riviere, A., Selak, M., Lantin, D., Leroy, F. & De Vuyst, L. Bifidobacteria and Butyrate-Producing Colon
270 Bacteria: Importance and Strategies for Their Stimulation in the Human Gut. *Frontiers in Microbiology* **7**,
271 979 (2016).
- 272 29 Lopez-Siles, M., Duncan, S. H., Garcia-Gil, L. J. & Martinez-Medina, M. Faecalibacterium prausnitzii: from
273 microbiology to diagnostics and prognostics. *Isme J* **11**, 841-852 (2017).
- 274 30 Li, Y. P. *et al.* Altered respiratory virome and serum cytokine profile associated with recurrent respiratory
275 tract infections in children. *Nat Commun* **10**, 2288 (2019).

276 **Figure legends**

277 **Fig. 1. Dirichlet multinomial mixtures (DMM) clustering analyses of 16S rRNA data separate**
278 **COVID-19 children into groups with distinctive features (N = 128).** a. Eight distinct clusters were
279 identified based on lowest Laplace approximation for control and patient samples from gut or nasal
280 and throat cavities. Heat map showing the relative abundance of 40 most dominant bacterial genera
281 per DMM cluster. The stars represent unclassified genera. H-GUT indicates abnormal gut microbial
282 community structure of healthy children. H-MIX represents normal microbial community structure
283 of a mixture of fecal, nasal and throat samples of healthy individuals. COVID-GUT I-III enriched in
284 fecal samples of COVID-19 children; COVID-TN I-III enriched in both nasal and throat samples of
285 COVID-19 children. b. Nonmetric multidimensional scaling (NMDS) visualization of DMM clusters
286 using Bray-Curtis distance of bacterial genera. Significant separation of microbial community
287 structures was implicated by the ANOSIM statistic R closer to 1 with < 0.05 P value. The stress value
288 lower than 0.2 provides a good representation in reduced dimensions. c. Box plots showing the alpha
289 diversity (richness and evenness) per each DMM cluster. Wilcoxon test was used to compare
290 difference of H-MIX cluster and others under three significance levels of * $P < 0.05$, ** $P < 0.01$, and
291 *** $P < 0.001$.

292
293 **Fig. 2. Identification (a) and relative abundance distribution (b) of indicator genera of eight**
294 **DMM clusters.** Indicators of eight microbial community types (DMM clusters) were identified from
295 top 40 genus contributing to DMM clustering in Fig.1a (See Supplementary Methods). Twenty-one
296 indicator genera are shared by two or more community types with similar diversity levels (e.g. II-III,
297 or I-H-MIX). Significance levels of indicators are as follows: * $P < 0.05$, ** $P < 0.01$, and *** $P <$

298 0.001.

299

300 **Fig. 3. Dynamic change of both DMM clusters (a) and six key taxa (b) in three body sites of**
301 **COVID-19 children.** Age (months) of each COVID-19 child was shown in brackets. The community
302 type levels were divergent between respiratory tract and gut (e.g. on days 11, 15 and 23 in CV04, and
303 days 16 and 42 in CV09). The respiratory microbiome appeared to be progressively worsening in
304 seven children (CV01-CV04 and CV07-CV09) for 25-42 days after symptom onset. The worsening
305 of the gut microbiome appeared in four children (CV03, CV04, CV07 and CV09), and sustained for
306 25-52 days. **b**, key taxa of DMM clusters were shown in eight COVID-19 children with at least two
307 time points of sampling. Linked to Supplementary Fig.2.

308

309 **Fig. 4. Co-occurrence network of gut, nasal and throat microbiotas in the progression of**
310 **COVID-19 children.** Positively correlated microbial pairs with both Pearson correlation r values
311 higher than 0.4 and FDR-adjusted P values lower than 0.001 were shown.

312 **Method**

313 **Study population**

314 Nine children were diagnosed as COVID-19 patients by Children's Hospital of Fudan University
315 according to the National Guidelines for Diagnosis and Treatment of COVID-19. A total of 103
316 samples, including 31 nasal swabs, 28 throat swabs and 44 feces, were collected from these patients
317 ([Supplementary Fig. S1](#)). Twenty-five samples from 14 age-matched healthy children were used as
318 controls. The respiratory samples were collected using flexible, sterile, dry swabs, which can reach
319 the posterior nasopharynx and oropharynx easily (approximately 2 inches). About 2 ml spontaneous,
320 unstimulated fecal specimen (300 mg/tube) was collected into a sterile cryogenic vial (Corning, NY,
321 USA), divided into aliquots and stored at -80°C until use. The sampling was performed by the
322 professionals at the hospital.

323 The study was approved by Children's Hospital of Fudan University (2020-27). Informed consents
324 were obtained from involved patients or their guardians.

325

326 **Confirmation of COVID-19 children**

327 The clinical and epidemiological characteristics, and SARS-CoV-2 RNA shedding patterns of these
328 patients were previously reported^{31,32}. All nine COVID-19 children had mild symptoms. The virus
329 RNA was extracted from all samples using a Mag-Bind RNA Extraction Kit (MACCURA, Sichuan,
330 China) according to the manufacturer's instructions. The *ORF1ab* and *N* genes of SARS-CoV-2 was
331 detected using a Novel Coronavirus (2019-nCoV) RNA detection Kit (PCR-Fluorescence Probing)
332 (DAAN gene, Guangzhou, China) according to the manufacturer's instructions.

333

334 **16S rRNA gene sequencing**

335 All samples including nasal swabs, throat swabs and stool samples were subjected to the DNA
336 extraction using a QIAamp DNA Microbiome Kit (QIAGEN, Düsseldorf, Germany). A novel triple-
337 index amplicon sequencing strategy was used for 16S rRNA gene sequencing³³. In brief, a set of
338 universal bacterial primers was used to amplify the V4 hypervariable region (515-806 nt) of the 16S
339 rRNA gene. Two rounds of PCR amplifications were performed³⁴. A reaction mixture containing 8
340 µL Nuclease-free water, 0.5 µL KOD-Plus-Neo (TOYOBO, Osaka Boseki, Japan), 2.5 µL of 1 µM
341 PCR1 forward primer, 2.5 µL of 1 µM PCR1 reverse primer, and 5 µL DNA template was prepared
342 for the first round of the PCR (PCR1) amplification. PCR1 products were purified using Monarch
343 DNA Gel Extraction Kit (New England Biolabs, Ipswich, MA, USA), and quantified by a Qubit®
344 4.0 Fluorometer (Invitrogen, Carlsbad, CA, USA). Purified PCR1 products were pooled with equal
345 amounts, and then subjected to the secondary round of PCR (PCR2) amplification. The PCR2 mix
346 contains 21 µL Nuclease-free water, 1 µL KOD-Plus-Neo (TOYOBO, Osaka Boseki, Japan), 5 µL of
347 1 µM PCR2 forward primer, 5 µL of 1 µM PCR2 reverse primer, and 5 µL pooled PCR1 products.
348 The PCR2 products were purified using the same Gel Extraction Kit and qualified using the Qubit®
349 4.0 Fluorometer. The specific products were further qualified using Agilent 2100 Bioanalyzer
350 (Agilent, Santa Clara, CA, USA). The PCR2 products with equal moles of specific products were
351 pooled and mixed them with AMPure XP beads (Beckman Coulter, Pasadena, CA, USA) in a ratio of
352 0.8:1. After purification, the amplicons were paired-end sequenced (2x250) using Illumina-P250
353 sequencer.

354

355 **Bioinformatic analysis of 16S rRNA gene sequence data**

356 Using USEARCH11 software³⁵ and FASTX-Toolkit³⁶, sequenced reads were merged, de-multiplexed
357 and filtered. After trimming barcode, adapter and primer sequences using USEARCH11, 14,702, 896
358 sequences were retained with an average of 100019 sequences per sample. Based on the Qiime2
359 platform³⁷, the Deblur³⁸ was used to cluster sequence data into sub-OTUs (operational taxonomic
360 units), better than traditional OTU picking usually according to 97% sequence similarity threshold
361 which may miss subtle and real biological sequence variation³⁹. In particular, we used the Deblur to
362 perform quality control, dereplicate, chimeras remove on with default settings except for truncating
363 sequence length to 250bp. A sub-OTU (sOTU) count table, equivalent to OTU table, was generated
364 (2187 sOTUs). The taxonomic classification of sOTU representative sequences was assigned by using
365 the RDP Naive Bayesian Classifier algorithm⁴⁰ based on the Ribosomal Database project (RDP) 16S
366 rRNA training set (v16) database⁴¹. Finally, the sOTU table were subsampled at an even depth of
367 3600 sequences per sample to eliminate the bias led by different sequencing depths among samples.
368 The sOTU coverage of 87% was sufficient to capture microbial diversity.

369

370 **Identification and characteristics of microbial community types**

371 Based on the bacterial genus abundance, we used the Dirichlet multinomial mixtures (DMM)⁴²
372 algorithm introduced by mothur⁴³ v1.44.1 to identify microbial community types because the DMM
373 algorithm could efficiently cluster samples based on microbial composition, whose sensitivity,
374 reliability and accuracy were widely confirmed in many microbiome studies^{16,44,45}. Based on the
375 lowest Laplace approximation index, the appropriate microbial community type numbers (DMM
376 clusters) were determined. Conjugated with the Analysis of Similarities (ANOSIM), the reliability of
377 DMM clustering was further validated and then visualized by the Non-metric multidimensional

378 scaling (NMDS) based on the Bray-Curtis distance under bacterial genus level. “The ANOSIM
379 statistic “R” compares the mean of ranked dissimilarities between groups to the mean of ranked
380 dissimilarities within groups. An R value close to “1.0” suggests dissimilarity between groups while
381 an R value close to “0” suggests an even distribution of high and low ranks within and between
382 groups⁴⁶. ANOSIM p values lower than 0.05 suggest the higher similarity within sites. Richness
383 (Observed sOTUs) and Pielou's or Species evenness for each community type were calculated for
384 estimating the difference of alpha diversity. Those analyses described above were performed using R
385 package “vegan” v2.5-6. Using R package ‘Pheatmap’, the dynamic change of microbial community
386 types and compositions were visualized. Alpha diversity difference between groups were measured
387 using the Wilcoxon Rank Sum Test in R.

388

389 **Identification of indicator taxa contributing to microbial community typing**

390 To get the reliable indicator genus for community typing, we performed the Indicator Species
391 Analysis using the indicpecies package (ver.1.7.8)⁴⁷ in R platform with top 40 genus contributing
392 to DMM clustering that accounted for 71% cumulative difference. Dynamic changes of indicator
393 genera corresponding to each community type were showed in all COVID-19 children using the
394 pheatmap package in R.

395

396 **Co-occurrence network analysis of microbiomes among gut, nasal, and throat of COVID-19** 397 **children**

398 Based on microbial genus abundances of gut, nasal, and throat samples collected from 8 COVID-19
399 children, we calculated the Pearson Correlation Coefficient (Pearson's r) among bacterial genera of

400 three body sites. The Pearson's r higher than 0.4 or lower than -0.4 with P values that were below
401 0.05 after the FDR adjustment were considered significant correlation. Co-occurrence network of
402 significantly correlated bacterial genus pairs was visualized using Cytoscape v3.8.0⁴⁸.

403

404 **Data availability**

405 The raw data of 16S rRNA gene sequences are available at NCBI Sequence Read Archive (SRA)
406 (<https://www.ncbi.nlm.nih.gov/sra/>) at BioProject ID [PRJNA642019](https://www.ncbi.nlm.nih.gov/bioproject/PRJNA642019).

407

- 408 31 Cai, J. *et al.* A Case Series of children with 2019 novel coronavirus infection: clinical and epidemiological
409 features. *Clin Infect Dis*, ciaa198 (2020).
- 410 32 Liu, P. *et al.* Dynamic surveillance of SARS-CoV-2 shedding and neutralizing antibody in children with
411 COVID-19. *Emerg Microbes Infect* **9**, 1254-1258 (2020).
- 412 33 D'Amore, R. *et al.* A comprehensive benchmarking study of protocols and sequencing platforms for 16S
413 rRNA community profiling. *Bmc Genomics* **17**, 55 (2016).
- 414 34 de Muinck, E. J., Trosvik, P., Gilfillan, G. D., Hov, J. R. & Sundaram, A. Y. M. A novel ultra high-throughput
415 16S rRNA gene amplicon sequencing library preparation method for the Illumina HiSeq platform.
416 *Microbiome* **5**, 68 (2017).
- 417 35 Edgar, R. C. UPARSE: highly accurate OTU sequences from microbial amplicon reads. *Nature Methods* **10**,
418 996-998 (2013).
- 419 36 Hannon, G. J. FASTX-Toolkit. http://hannonlab.cshl.edu/fastx_toolkit (2010).
- 420 37 Caporaso, J. G. *et al.* QIIME allows analysis of high-throughput community sequencing data. *Nature*
421 *Methods* **7**, 335-336 (2010).
- 422 38 Amir, A. Deblur rapidly resolves single-nucleotide community sequence patterns. *mSystems*. **2** (2017).
- 423 39 Knight, R. *et al.* Best practices for analysing microbiomes. *Nature Reviews Microbiology* **16**, 410-422
424 (2018).
- 425 40 Wang, Q., Garrity, G. M., Tiedje, J. M. & Cole, J. R. Naïve Bayesian Classifier for Rapid Assignment of rRNA
426 Sequences into the New Bacterial Taxonomy. *Applied and Environmental Microbiology* **73**, 5261 (2007).
- 427 41 Cole, J. R. *et al.* Ribosomal Database Project: data and tools for high throughput rRNA analysis. *Nucleic*
428 *Acids Research* **42**, D633-D642 (2013).
- 429 42 Holmes, I., Harris, K. & Quince, C. Dirichlet Multinomial Mixtures: Generative Models for Microbial
430 Metagenomics. *PLoS ONE* **7**, e30126 (2012).
- 431 43 Schloss, P. D. *et al.* Introducing mothur: open-source, platform-independent, community-supported
432 software for describing and comparing microbial communities. *Appl Environ Microbiol* **75**, 7537-7541
433 (2009).
- 434 44 Ding, T. & Schloss, P. D. Dynamics and associations of microbial community types across the human body.
435 *Nature* **509**, 357-360 (2014).
- 436 45 Fujimura, K. E. *et al.* Neonatal gut microbiota associates with childhood multisensitized atopy and T cell

- 437 differentiation. *Nature Medicine* **22**, 1187-1191 (2016).
438 46 Clarke, K. R. Non-parametric multivariate analyses of changes in community structure. *Australian Journal*
439 *of Ecology* **18**, 117-143 (1993).
440 47 De Cáceres, M., Legendre, P. & Moretti, M. Improving indicator species analysis by combining groups of
441 sites. *Oikos* **119**, 1674-1684 (2010).
442 48 Otasek, D., Morris, J. H., Boucas, J., Pico, A. R. & Demchak, B. Cytoscape Automation: empowering
443 workflow-based network analysis. *Genome Biol* **20**, 185 (2019).
444

445 **Author contributions** C.Z. conceived the study idea. C.Z., Z.Z. and J.X designed and supervised the
446 study. P.L., M.Z. and J.X collected clinical samples and data. R.X., P.L. and Y.M. performed the
447 experiments. T.Z. and Q.W. processed and analyzed the raw sequencing data. R.X., P.L., J.X. and
448 M.Z. analyzed the clinical data. C.Z., Z.Z. and X.J. interpreted the data. Z.Z. and R.X. generated the
449 figures. C.Z., Z.Z., R.X., and T.Z. wrote the first draft of the manuscript. X.J. contributed to critical
450 revision. All authors contributed to the final manuscript.

451

452 **Acknowledgements** We thank Mr. Kai Liu and Mrs. Xiuming Wu at Institut Pasteur of Shanghai,
453 Chinese Academy of Sciences for their technical support. This work was supported by the grants from
454 the National Key Research and Development Program of China (2017ZX10103009-002 and
455 2018YFC2000500), the Second Tibetan Plateau Scientific Expedition and Research (STEP) program
456 (2019QZKK0503), the Key Research Program of the Chinese Academy of Sciences (FZDSW-219),
457 the Chinese National Natural Science Foundation (31970571) and grants specific for Coronavirus
458 Disease 2019 from the Children's Hospital of Fudan University (Grant No. EKXGZX006).

459

460 **Competing interests** The authors declare no competing interests.

461

462 **Additional information**

463 **Supplementary Table S1. Fecal, nasal, and throat microbial abundances (phyla and genera).**

464 The stars represent unclassified genera.

465 **Supplementary Fig. S1. COVID-19 patient admission and discharge times as well as the**
466 **detection of SARS-CoV-2.** DAY 1 was the day of symptom onset.

467 **Supplementary Fig. S2. Dynamic change of 26 indicator genera in three body sites of nine**
468 **COVID-19 children.** Linked to Fig.2a and Fig.3b. The stars represent unclassified genera.

469 **Supplementary Fig. S3. Distinct gut and respiratory microbiome mechanisms associated with**

470 **the progress of COVID-19 in adults and children.** The dynamic mechanism of the microbiome in

471 adults was interpreted from our recent observation based on the longitudinal throat and anal swabs

472 from 35 adults with COVID-19 (Xu et al. unpublished data). Similar community types from I to III/IV

473 indicate a progressive dysbiosis of the microbiome. In mild adults with COVID-19, a synchronous

474 shift of community type from early dysbiosis towards late incomplete restoration was found in both

475 respiratory and gut microbiomes within a short time. In children, however, the changes of the

476 community types were divergent between the respiratory tract and gut, possibly implying that the

477 “airway-gut axis” is still not established during the childhood. Moreover, children’s respiratory

478 microbiome appeared to be progressively worsening for a long period despite a fast clinical recovery.




Fig.1



Fig. 2

Fig. 3






Fig.4



Indicator Colors

● H-GUT
 ● H-MIX
 ● COVID-GUT-I
 ● COVID-GUT-II
 ● COVID-GUT-III
 ● COVID-TN-I
 ● COVID-TN-II
 ● COVID-TN-III